Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Safety and efficacy of preoperative chemotherapy with SOX+Cetuximab in patients with liver-only metastases(H2,H3), KRAS-WT from colorectal cancer(KSCC1002)

ABSTRACT: Interventions: L-OHP 130mg/m2 i.v. (day1) Cmab 250mg/m2 i.v. (only the first time Cmab 400mg/m2) S-1 80mg/m2 (day1-14) to be repeated every 3 weeks for 4 cycles. Surgery was planned after SOX+Cetuximab therapy. Primary outcome(s): Liver resection rate Study Design: Single arm Non-randomized

DISEASE(S): Patients With Liver-only Metastases From Colorectal Cancer

PROVIDER: 2619781 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Phase II trial of S-1+oxaliplatin+Cetuximab as first-line treatment in patients with kras-wild type unresectable advanced colorectal cancer - KODK 9 -

Project description:Interventions: (SOX+Cmab) L-OHP 85mg/m2 i.v.(day1) Cmab 500mg/m2 i.v.(day1) S-1 80mg/m2(day1-7) to be repeated every 2 weeks Primary outcome(s): Response rate Study Design: Single arm Non-randomized

| 2624365 | ecrin-mdr-crc

A phase II Study of Useful therapeutic strategy for metastatic Colorectal Cancer to Evaluate Oxaliplatin Stop and Go in SOX+Bmab

Project description:Interventions: TS-1 80mg/m2/day (day1-14) and Oxaliplatin 130mg/m2 (day1) and Bevacizumab 7.5mg/kg (day1) every 21 days for 4 courses followed by TS-1 80mg/m2/day (day1-14) and Bevacizumab 7.5mg/kg (day1) every 21 days for 8 courses. And next, administer until PD the same SOX+Bmab regimen. Primary outcome(s): Progression-free Survival Study Design: Single arm Non-randomized

| 2622829 | ecrin-mdr-crc

The randomized phaseII study of SOX and SIR sequential therapy as TS-1 based regimens in Advanced Colorectal Cancer; WSTAR trial

Project description:Interventions: 1st line chemotheraypy: SOX+Bmab Bmab: 7.5mg/kg every 3weeks L-OHP: 130mg/m2 every 3weeks TS-1: 80-120mg/day 14days on, 7days off 21st 1 course. 2nd line chemotheraypy: SIR+Bmab Bmab: 7.5mg/kg every 3weeks CPT-11: 150mg/m2 every 3weeks TS-1: 80-120mg/day 14days on, 7days off 21st 1 course. 2nd line chemotherapy: choose either (did not use by) 1)SIR+Bmab Bmab: 7.5mg/kg every 3 weeks CPT-11: 150mg/m2 every 3weeks TS-1: 80-120mg/day 14days on, 7 days off 21st 1 course. 2) SIR+Cmab Cmab: 250mg/m2 every week CPT-11: 150mg/m2 every 3 weeks TS-1: 80-120mg/day 14days on, 7days off 21st 1 course. 3)SIR+Pmab Pmab: 6mg/kg every 2 weeks CPT-11: 150mg/m2 every 3 weeks TS-1: 80-120mg/day 14days on, 7days off 21st 1 course 4)SIR CPT-11: 150mg/m2 every 3 weeks TS-1: 80-120mg/day 14days on, 7 days off 21st 1 course. 5)SOX+Bmab Bmab: 7.5mg/kg every 3 weeks L-OHP: 130mg/m2 every 3 weeks TS-1: 80-120mg/day 14days on, 7 days off 21st 1 course. 6)SOX+Cmab Cmab: 250mg/m2 every 2 weeks L-OHP: 130mg/m2 every 3 weeks TS-1: 80-120mg/day 14days on, 7days off 21st 1 course. 7)SOX+Pmab Pmab: 6mg/kg every 2 weeks L-OHP: 130mg/m2 every 3 weeks TS-1: 80-120mg/day 14 days on, 7days off 21st 1 course 8)SOX L-OHP: 130mg/m2 every 3 weeks TS-1: 80-120mg/day 14 days on, 7days off 21st 1 course Primary outcome(s): Overall survival:OS Study Design: Parallel Randomized

| 2623112 | ecrin-mdr-crc

Multicenter Phase II study of combination therapy with S-1 plus Irinotecan plus Cetuximab (MetronomicIRIS/Cmab combination therapy) in patients with KRAS wild type unresectable colorectal cancer, who had previously received on fluoropyrimidine , oxaliplatin , irinotecan and bevacizumab. (KSCOG CR-06)

Project description:Interventions: MetronomicIRIS(S-1/CPT-11)/Cmab combination therapy S-1:50 or 60 or 80mg/body/day(day3-7,10-14,17-21,24-28) CPT-11:60mg/m2(day1,8,15) Cmab*:250mg/m2(day1,8,15,22) *:400mg/m2 for the initial dosing(day1) every 4 weeks Primary outcome(s): Progression free survival Study Design: Single arm Non-randomized

| 2627425 | ecrin-mdr-crc

Randomized phase II study of adding steroid for prevention of venous pain in colorectal cancer patients who are receiving oxaliplatin through peripheral vein (APOLLO)

Project description:Interventions: XELOX Oxaliplatin 130mg/m2 day1 Capecitabine 2,000mg/m2 day1-14 every 3 weeks SOX Oxaliplatin 130mg/m2 day1 S-1 80-120mg/m2 day1-14 every 3 weeks Oxaliplatin is combined with dexamethasone (2 mg). XELOX Oxaliplatin 130mg/m2 day1 Capecitabine 2,000mg/m2 day1-14 every 3 weeks SOX Oxaliplatin 130mg/m2 day1 S-1 80-120mg/m2 day1-14 every 3 weeks Primary outcome(s): The incidence of venous pain:Grade>=2 Study Design: Parallel Randomized

| 2619736 | ecrin-mdr-crc

Phase2 study of perioperative chemotherapy with SOX and operation for Stage3 colorectal cancer(SOS3)

Project description:Interventions: Oxaliplatin 130mg/m2i.v.(day1) TS-1 80mg/m2 p.o.(day1-14) drug holidays (day15-21) to be repeated every 3 weeks Primary outcome(s): Response Rate,Safety Study Design: Single arm Non-randomized

| 2622213 | ecrin-mdr-crc

A randomized phase II study of XELOX plus Bevacizumab versus XELIRI plus Bevacizumab for advanced colorectal cancer with or without mitochondrial transcription factor A (mtTFA) expression.

Project description:Interventions: mtTFA(+):Oxaliplatin 130mg/m2 i.v. (day1) Bevaciumab 7.5mg/Kg i.v. (day1) Capecitabine2,000mg/m2 p.o.(day1-14) to be repeated every 3 weeks until progression mtTFA(+):Irinotecan 200mg/m2 i.v. (day1) Bevaciumab 7.5mg/Kg i.v. (day1) Capecitabine1,600mg/m2 p.o.(day1-14) to be repeated every 3 weeks until progression mtTFA(-):Oxaliplatin 130mg/m2 i.v. (day1) Bevaciumab 7.5mg/Kg i.v. (day1) Capecitabine2,000mg/m2 p.o.(day1-14) to be repeated every 3 weeks until progression mtTFA(-):Irinotecan 200mg/m2 i.v. (day1) Bevaciumab 7.5mg/Kg i.v. (day1) Capecitabine1,600mg/m2 p.o.(day1-14) to be repeated every 3 weeks until progression Primary outcome(s): Response rate with or without mtTFA expression Study Design: Parallel Randomized

| 2620502 | ecrin-mdr-crc

A validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone. (AVOID)

Project description:Interventions: Dexamethasone 13.2mg/body i.v.(day1) Oxaliplatin 130mg/m2 i.v. (day1) Bevaciumab 7.5mg/Kg i.v. (day1) Capecitabine2,000mg/m2,p.o.(day1-14) to be repeated every 3 weeks Primary outcome(s): Hypersensitivity reaction incidence Study Design: Single arm Non-randomized

| 2625136 | ecrin-mdr-crc

Clinical study on medical value of adoptive immunotherapy with chemotherapy for stage IV colorectal cancer

Project description:Interventions: Oxaliplatin 130mg/m2 i.v. (day1) Bevaciumab 7.5mg/Kg i.v. (day1) Capecitabine2,000mg/m2,p.o.(day1-14) Autologous alfa/beta T cells i.v. to be repeated every 3 weeks Primary outcome(s): Safety Study Design: Single arm Non-randomized

| 2626285 | ecrin-mdr-crc

Pilot study of early start of chemotherapy after excision of the primary colorectal cancer. (Pearl star 01)

Project description:Interventions: Oxaliplatin 130mg/m2 i.v. (day1) Bevaciumab 7.5mg/Kg i.v. (day1) Capecitabine2,000mg/m2 p.o.(day1-14) to be repeated every 3 weeks Primary outcome(s): Safety Study Design: Single arm Non-randomized

| 2619811 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data